| Dr Sylvia Anagnos, MD | |
|
777 Kimole Ln Ste 250, Adrian, MI 49221-1400 | |
| (419) 291-3900 | |
| (419) 479-6055 |
| Full Name | Dr Sylvia Anagnos |
|---|---|
| Gender | Female |
| Speciality | Neurology |
| Experience | 38 Years |
| Location | 777 Kimole Ln Ste 250, Adrian, Michigan |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1255428967 | NPI | - | NPPES |
| 2953325 | Medicaid | MI |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | 4301059517 (Michigan) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Emma L Bixby Medical Center | Adrian, MI | Hospital |
| Promedica Toledo Hospital | Toledo, OH | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Promedica Central Physicians | 2365348190 | 818 |
News Archive
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company has resubmitted the New Drug Application for Intermezzo (zolpidem tartrate sublingual tablet) to the U.S. Food and Drug Administration.
When trauma spills the contents of our cell powerhouses, it can evoke a potentially deadly immune response much like a severe bacterial infection.
An orphan drug originally used for HIV treatment has been found to short-circuit the process that results in additional sensitivity and pain from opioid use. The study by researchers at the Indiana University School of Medicine is reported in the March 25, 2011 issue of Brain, Behavior and Immunity.
For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized gas - and chemo therapy on aggressive brain tumour cells.
Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.
› Verified 6 days ago
| Entity Name | W.a. Foote Memorial Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1326078866 PECOS PAC ID: 0244136067 Enrollment ID: O20031211000174 |
News Archive
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company has resubmitted the New Drug Application for Intermezzo (zolpidem tartrate sublingual tablet) to the U.S. Food and Drug Administration.
When trauma spills the contents of our cell powerhouses, it can evoke a potentially deadly immune response much like a severe bacterial infection.
An orphan drug originally used for HIV treatment has been found to short-circuit the process that results in additional sensitivity and pain from opioid use. The study by researchers at the Indiana University School of Medicine is reported in the March 25, 2011 issue of Brain, Behavior and Immunity.
For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized gas - and chemo therapy on aggressive brain tumour cells.
Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.
› Verified 6 days ago
| Entity Name | W.a. Foote Memorial Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1760437826 PECOS PAC ID: 0244136067 Enrollment ID: O20031212000691 |
News Archive
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company has resubmitted the New Drug Application for Intermezzo (zolpidem tartrate sublingual tablet) to the U.S. Food and Drug Administration.
When trauma spills the contents of our cell powerhouses, it can evoke a potentially deadly immune response much like a severe bacterial infection.
An orphan drug originally used for HIV treatment has been found to short-circuit the process that results in additional sensitivity and pain from opioid use. The study by researchers at the Indiana University School of Medicine is reported in the March 25, 2011 issue of Brain, Behavior and Immunity.
For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized gas - and chemo therapy on aggressive brain tumour cells.
Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.
› Verified 6 days ago
| Entity Name | Promedica Central Physicians |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1043270150 PECOS PAC ID: 2365348190 Enrollment ID: O20110310000073 |
News Archive
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company has resubmitted the New Drug Application for Intermezzo (zolpidem tartrate sublingual tablet) to the U.S. Food and Drug Administration.
When trauma spills the contents of our cell powerhouses, it can evoke a potentially deadly immune response much like a severe bacterial infection.
An orphan drug originally used for HIV treatment has been found to short-circuit the process that results in additional sensitivity and pain from opioid use. The study by researchers at the Indiana University School of Medicine is reported in the March 25, 2011 issue of Brain, Behavior and Immunity.
For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized gas - and chemo therapy on aggressive brain tumour cells.
Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Sylvia Anagnos, MD 333 N Summit St Fl 7, Toledo, OH 43604-1531 Ph: (844) 373-0871 | Dr Sylvia Anagnos, MD 777 Kimole Ln Ste 250, Adrian, MI 49221-1400 Ph: (419) 291-3900 |
News Archive
Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of proprietary products that address important therapeutic needs in the field of neuroscience, today announced that the company has resubmitted the New Drug Application for Intermezzo (zolpidem tartrate sublingual tablet) to the U.S. Food and Drug Administration.
When trauma spills the contents of our cell powerhouses, it can evoke a potentially deadly immune response much like a severe bacterial infection.
An orphan drug originally used for HIV treatment has been found to short-circuit the process that results in additional sensitivity and pain from opioid use. The study by researchers at the Indiana University School of Medicine is reported in the March 25, 2011 issue of Brain, Behavior and Immunity.
For the first time, physicists from the Max Planck Institute for Extraterrestrial Physics (MPE), biologists and physicians demonstrated the synergistic effect of cold atmospheric plasma - a partly ionized gas - and chemo therapy on aggressive brain tumour cells.
Kraig Biocraft Laboratories, Inc., a biotechnology company focused on the development of commercially significant high performance polymers and technical fiber including spider silk, is very pleased to announce that its S1 registration statement has been declared effective. The Company filed the S1 registration statement in October of 2009 and has been working diligently over the last nine months to obtain this clearance.
› Verified 6 days ago
Dr. Maureen Salopek Noble, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1040 S Winter St, Suite 1022, Adrian, MI 49221 Phone: 517-263-8905 | |
Dr. Theethaye Lonappan Ittiara, M.D Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 142 E Maumee St, Adrian, MI 49221 Phone: 517-263-5810 | |
Dr. Moina Hassan, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1040 S Winter St, Adrian, MI 49221 Phone: 517-263-8905 Fax: 517-263-7616 | |
Thresiamma Jacob, M.D. Psychiatry & Neurology Medicare: Not Enrolled in Medicare Practice Location: 142 E Maumee St, Adrian, MI 49221 Phone: 517-263-5810 | |
Manish Prasad, M.D. Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1040 S Winter St, Adrian, MI 49221 Phone: 517-263-8905 | |
Luven Marie Sequerra Tejero, MD Psychiatry & Neurology Medicare: Accepting Medicare Assignments Practice Location: 1040 S Winter St, Adrian, MI 49221 Phone: 517-263-8905 |